Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2007 Jul;44(7):467-71.
doi: 10.1136/jmg.2006.048173. Epub 2007 Feb 16.

Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations

Luna Kadouri, Ayala Hubert, Yakir Rotenberg, Tamar Hamburger, Michal Sagi, Chovav Nechushtan, Dvorah Abeliovich, Tamar Peretz
Comparative Study

Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations

Luna Kadouri et al. J Med Genet. 2007 Jul.

Abstract

Background: The risks for cancers other than breast (BC) or ovarian (OC) cancer in breast cancer gene 1 and 2 (BRCA1/2) mutation carriers were elevated in studies of carrier families. However, case-control studies did not confirm this observation.

Objective: To compare the risks for other cancers in BRCA1/2 mutation carriers and non-carriers, all affected with BC and/or OC. Both groups share risk modifiers of BC/OC, which enabled assessment of the role of BRCA1/2 mutations.

Methods: 1098 Ashkenazi Jewish women affected with BC and/or OC were ascertained during 1995-2003; molecular testing revealed 229 BRCA1 and 100 BRCA2 carriers and 769 non-carriers. COX proportional hazard models were used to evaluate the risk of other cancers. Analyses were conducted including all other cancers or only those diagnosed after BC/OC diagnosis.

Results: The HRs for any other cancer were 2.6 (95% CI 1.7 to 4.2, p<0.001) and 1.8 (95% CI 0.95 to 3.6, p = 0.07) in BRCA1 and BRCA2 carriers, respectively. The corresponding colon cancer HRs were 3.9 (95% CI 1.3 to 12.1, p = 0.02) and 2.3 (95% CI 0.5 to 11.3, p = 0.3) in BRCA1 and BRCA2 carriers. The HR for lymphoma was 11.9 (95% CI 3.1 to 46.2, p = 0.001) in BRCA2 carriers. Risk estimates for other cancers after the onset of BC/OC were similar.

Conclusion: A 2.5-fold increase in any other cancer and a fourfold risk of colon cancer were found among BRCA1 carriers. The corresponding HRs in BRCA2 carriers were non-significant, except for the markedly elevated risk of lymphoma. These results suggest a role for BRCA1/2 mutations in colorectal cancer risk in a subgroup of BC/OC-affected carriers.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Brose M S, Rebbeck T R, Calzone K A, Stopfer J E, Nathanson K L, Weber B L. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002941365–1372. - PubMed
    1. Thompson D, Easton D F. The Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002941358–1365. - PubMed
    1. Struewing J P, Hartge P, Wacholder S, Baker S M, Berlin M, McAdams M, Timmerman N M, Brody L C, Tucker M A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 19973361401–1408. - PubMed
    1. The Breast Cancer Linkage Consortium Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999911310–1316. - PubMed
    1. Ford D, Easton D F, Bishop D T, Narod S A, Goldberg D E. Risks of cancer in BRCA1‐mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994343692–695. - PubMed